%0 Journal Article
%T NAP1L1在肝癌中的生物信息学分析<br>Bioinformatics Analysis of NAP1L1 in Hepatocellular Carcinoma
%A 钟文钧
%A 陈亚峰
%A 李江斌
%A 董瑞
%J Advances in Clinical Medicine
%P 9325-9336
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.12101350
%X 目的：探讨核小体组装蛋白1样蛋白1 (nucleosomeassemblyprotein1-like1, NAP1L1)分子在肝细胞癌(Hepatocellular carcinoma, HCC)中的表达以及临床预后意义。方法：我们利用UALCA和TIMER 2.0数据库探索了NAP1L1在HCC中的mRNA表达。cBioPortal数据库用于分析HCC中NAP1L1相关基因突变的影响。用STRING、GEPIA和DAVID数据库构建PPI网络并进行富集分析。然后使用TIMER 2.0和GEPIA 2.0数据库研究免疫浸润水平和免疫状态。最后，通过使用UALCAN、GEPIA和Kaplan-Meier数据库探索了患者预后的情况。结果：我们确定NAP1L1在肝癌中差异表达(P &lt; 0.05)，与患者免疫细胞浸润程度、免疫状态、临床病理特征以及较差生存预后显著相关(P &lt; 0.05)，与NAP1L1共表达的基因参与调控核糖体生物过程、分子结合、调节翻译起始因子活性等过程(P &lt; 0.05)。结论：这些结果表明NAP1L1可能在控制免疫细胞浸润以及调节免疫功能方面发挥重要作用，因此NAP1L1可作为HCC有价值的预后生物标志物和潜在免疫治疗靶点。<br />
Objective: To investigate the expression of nucleosome assembly protein1-like1 (NAP1L1) molecule in hepatocellular carcinoma (HCC) and its clinical prognostic significance. Methods: We explored the mRNA expression of NAP1L1 in HCC using the UALCA and TIMER 2.0 databases. cBioPortal database was used to analyze the impact of NAP1L1-related gene mutations in HCC. The STRING, GEPIA and DAVID databases were used to construct PPI networks and perform enrichment analysis. TIMER 2.0 and GEPIA 2.0 databases were then used to study the level of immune infiltration and immune sta-tus. Finally, patient prognosis was explored by using the UALCAN, GEPIA, and Kaplan-Meier data-bases. Results: We determined that NAP1L1 was differentially expressed in HCC (P &lt; 0.05) and sig-nificantly related with immune cell infiltration, immune status, clinicopathological features, and poorer survival prognosis of patients (P &lt; 0.05), and that genes co-expressed with NAP1L1 were in-volved in regulating ribosomal activities, molecular binding, and translation initiation factor activi-ty regulation (P &lt; 0.05). Conclusion: These findings imply that NAP1L1 may be crucial in regulating immunological activity, and therefore NAP1L1 could be a useful predictive biomarker for HCC, as well as a possible immunotherapeutic target.
%K NAP1L1，预后，免疫浸润水平，肝细胞癌<br>NAP1L1
%K Prognosis
%K Immune Infiltration Level
%K Hepatocellular Carcinoma
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=56838